Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

Both studies are randomized, double-blind, placebo-controlled, dose-ranging, multi-national, multi-center trials, with the goal of obtaining substantial evidence of safety and efficacy for their respective indications.

The company also announced that it will establish two subsidiary companies: one in Germany to manage clinical studies in European countries and a second in the United States. Establishment of these subsidiaries will enable the company to take a vital step towards its planned full-scale global drug development. Y's Therapeutics also expects these operations to include business development and non-clinical & clinical development functions, as well as in-house lab function capability to enhance drug development.

"We recognized early on the importance of designing and conducting clinical trials on a very broad scale," stated Mr. Masanori Murayama, Co-founder, President and CEO of Y's Therapeutics. "By establishing a global clinical network, we can optimize and accelerate the clinical proof of concept stage for the drugs in development."

YSIL6 is a small-molecule drug in development for the treatment of inflammatory diseases, including rheumatoid arthritis and psoriasis. The molecule works by inhibiting TNF-alpha and IL-6 production in T-cells and macrophages, and by inhibiting T-cell proliferation and migration.

YSTH2 is a small-molecule drug in development for treatment of asthma and other diseases in which Th-2 type cytokine imbalance is suspected. The molecule works by inhibiting T-cell proliferation and migration, and by inhibiting Th-2 type and proinflammatory cytokine production, while exerting no effect on Th-1 type cytokine production.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 vaccination linked to reduced symptomatic child asthma